A Phase 1 interventional study of Dabigatran etexilate plus dronedarone and Dabigatran etexilate in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-06.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the study is to assess the relative bioavailability of a single dose of dabigatran after concomitant multiple oral administration of dronedarone with the aim to investigate whether and to what extent the P-gp inhibitor dronedarone affects pharmacokinetic parameters of dabigatran when administered to healthy subjects
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Capsule, oral administration with 240 mL water
Drug: Dabigatran etexilate
Capsule and Tablets, oral administration with 240 mL water
Drug: Dabigatran etexilate plus dronedarone
Capsule and Tablets, oral administration with 240 mL water
Drug: Dabigatran etexilate plus dronedarone
Capsule and Tablets, oral administration with 240 mL water
Drug: Dabigatran etexilate plus dronedarone
Capsule and Tablets, oral administration with 240 mL water
Drug: Dabigatran etexilate plus dronedarone
Drug pages: Dabigatran · Dronedarone
dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
150 mg as single dose
Drug pages: Dabigatran · Dronedarone
dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
Drug pages: Dabigatran · Dronedarone
dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
Drug pages: Dabigatran · Dronedarone
dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)
Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity.
Time frame: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration
Total Dabigatran: Maximum Measured Concentration (Cmax)
Maximum measured concentration of total dabigatran in plasma, per period.
Time frame: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration
Free Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞)
Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity.
Time frame: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration
Free Dabigatran: Maximum Measured Concentration (Cmax)
Maximum measured concentration of free dabigatran in plasma, per period.
Time frame: 1 h before drug administration and 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 36:00, 48:00 h after drug administration
| Milestone | TrtA -- TrtB -- TrtD -- TrtE | TrtA -- TrtC -- TrtE -- TrtD | TrtB -- TrtD -- TrtE -- TrtA | TrtC -- TrtE -- TrtD -- TrtA |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 9 | 9 | 9 | 8 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Milestone | TrtA -- TrtB -- TrtD -- TrtE | TrtA -- TrtC -- TrtE -- TrtD | TrtB -- TrtD -- TrtE -- TrtA | TrtC -- TrtE -- TrtD -- TrtA |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 8 |
| Completed | 9 | 8 | 9 | 8 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Non-compliance to protocol | 0 | 1 | 0 | 0 |
| Milestone | TrtA -- TrtB -- TrtD -- TrtE | TrtA -- TrtC -- TrtE -- TrtD | TrtB -- TrtD -- TrtE -- TrtA | TrtC -- TrtE -- TrtD -- TrtA |
|---|---|---|---|---|
| Started | 9 | 8 | 9 | 8 |
| Completed | 9 | 8 | 9 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | TrtA -- TrtB -- TrtD -- TrtE | TrtA -- TrtC -- TrtE -- TrtD | TrtB -- TrtD -- TrtE -- TrtA | TrtC -- TrtE -- TrtD -- TrtA |
|---|---|---|---|---|
| Started | 9 | 8 | 9 | 8 |
| Completed | 9 | 8 | 9 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | TrtA -- TrtB -- TrtD -- TrtE | TrtA -- TrtC -- TrtE -- TrtD | TrtB -- TrtD -- TrtE -- TrtA | TrtC -- TrtE -- TrtD -- TrtA |
|---|---|---|---|---|
| Started | 9 | 8 | 9 | 8 |
| Completed | 9 | 8 | 9 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | TrtA -- TrtB -- TrtD -- TrtE | TrtA -- TrtC -- TrtE -- TrtD | TrtB -- TrtD -- TrtE -- TrtA | TrtC -- TrtE -- TrtD -- TrtA |
|---|---|---|---|---|
| Started | 9 | 8 | 9 | 8 |
| Completed | 9 | 8 | 9 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
Area under the concentration-time curve of total dabigatran in plasma over the time interval from 0 extrapolated to infinity.
| ng*hr/mL | 150mg DE (TrtA) | 150mg DE + 400mg DR (TrtB) | 150mg DE + 400mg DR 2h Later (TrtC) | 150mg DE + 400mg DR Bid Same Time (TrtD) | 150mg DE + 400mg DR Bid 2h Later (TrtE) |
|---|---|---|---|---|---|
| Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞) | 1160 ± 40.3 | 2520 ± 27.1 | 1440 ± 40.3 | 2570 ± 28.1 | 1510 ± 32.9 |
Maximum measured concentration of total dabigatran in plasma, per period.
| ng/mL | 150mg DE (TrtA) | 150mg DE + 400mg DR (TrtB) | 150mg DE + 400mg DR 2h Later (TrtC) | 150mg DE + 400mg DR Bid Same Time (TrtD) | 150mg DE + 400mg DR Bid 2h Later (TrtE) |
|---|---|---|---|---|---|
| Total Dabigatran: Maximum Measured Concentration (Cmax) | 149 ± 46.0 | 282 ± 30.1 | 166 ± 37.5 | 288 ± 29.9 | 163 ± 30.9 |
Area under the concentration-time curve of free dabigatran in plasma over the time interval from 0 extrapolated to infinity.
| ng*hr/mL | 150mg DE (TrtA) | 150mg DE + 400mg DR (TrtB) | 150mg DE + 400mg DR 2h Later (TrtC) | 150mg DE + 400mg DR Bid Same Time (TrtD) | 150mg DE + 400mg DR Bid 2h Later (TrtE) |
|---|---|---|---|---|---|
| Free Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞) | 919 ± 47.5 | 2110 ± 27.4 | 1110 ± 47.2 | 2100 ± 30.5 | 1260 ± 36.0 |
Maximum measured concentration of free dabigatran in plasma, per period.
| ng/mL | 150mg DE (TrtA) | 150mg DE + 400mg DR (TrtB) | 150mg DE + 400mg DR 2h Later (TrtC) | 150mg DE + 400mg DR Bid Same Time (TrtD) | 150mg DE + 400mg DR Bid 2h Later (TrtE) |
|---|---|---|---|---|---|
| Free Dabigatran: Maximum Measured Concentration (Cmax) | 126 ± 48.0 | 239 ± 27.6 | 133 ± 40.7 | 241 ± 29.5 | 138 ± 34.0 |
Collected over 14 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 150mg DE (TrtA) | — | 0/35 (0%) | 3/35 (8.6%) |
| 150mg DE + 400mg DR (TrtB) | — | 0/18 (0%) | 6/18 (33.3%) |
| 150mg DE + 400mg DR 2h Later (TrtC) | — | 0/17 (0%) | 5/17 (29.4%) |
| 150mg DE + 400mg DR Bid Same Time (TrtD) | — | 0/34 (0%) | 5/34 (14.7%) |
| 150mg DE + 400mg DR Bid 2h Later (TrtE) | — | 0/30 (0%) | 3/30 (10%) |
| 400mg DR + 400mg DR Bid 2h Later (TrtE2) | — | 0/4 (0%) | 0/4 (0%) |
| Event | 150mg DE (TrtA) | 150mg DE + 400mg DR (TrtB) | 150mg DE + 400mg DR 2h Later (TrtC) | 150mg DE + 400mg DR Bid Same Time (TrtD) | 150mg DE + 400mg DR Bid 2h Later (TrtE) | 400mg DR + 400mg DR Bid 2h Later (TrtE2) |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/35 | 4/18 | 1/17 | 2/34 | 2/30 | 0/4 |
| Atrioventricular block first degreeCardiac disorders | 0/35 | 0/18 | 1/17 | 0/34 | 0/30 | 0/4 |
| PalpitationsCardiac disorders | 0/35 | 0/18 | 1/17 | 0/34 | 0/30 | 0/4 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/35 | 0/18 | 1/17 | 1/34 | 0/30 | 0/4 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 0/35 | 0/18 | 1/17 | 0/34 | 0/30 | 0/4 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/35 | 0/18 | 1/17 | 0/34 | 0/30 | 0/4 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/35 | 1/18 | 1/17 | 0/34 | 0/30 | 0/4 |
| Gastric disorderGastrointestinal disorders | 0/35 | 1/18 | 1/17 | 0/34 | 1/30 | 0/4 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/35 | 0/18 | 1/17 | 0/34 | 0/30 | 0/4 |
| MenorrhagiaReproductive system and breast disorders | 0/35 | 0/18 | 1/17 | 0/34 | 0/30 | 0/4 |
Treated set contains of all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.
| Age, Continuous(Years) | TrtA -- TrtB -- TrtD -- TrtE | TrtA -- TrtC -- TrtE -- TrtD | TrtB -- TrtD -- TrtE -- TrtA | TrtC -- TrtE -- TrtD -- TrtA | Total |
|---|---|---|---|---|---|
| Mean | 32.2 ± 10.7 | 37.8 ± 10.4 | 38.1 ± 9.7 | 33.3 ± 7.9 | 35.4 ± 9.6 |
| Sex: Female, Male(Participants) | TrtA -- TrtB -- TrtD -- TrtE | TrtA -- TrtC -- TrtE -- TrtD | TrtB -- TrtD -- TrtE -- TrtA | TrtC -- TrtE -- TrtD -- TrtA | Total |
|---|---|---|---|---|---|
| Female | 7 | 5 | 2 | 5 | 19 |
| Male | 2 | 4 | 7 | 4 | 17 |
The record gives a start of Feb 2011 and a primary completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dabigatran · Dronedarone